clinical trial · NCT07735533
A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies
Umoja Biopharma·phase2·not yet recruiting·n = 274
Lymphoma, B CellLymphoma Non-HodgkinHigh Grade B Cell LymphomaRichter Transformation LymphomaGrade 3b Follicular LymphomaPrimary Mediastinal B Cell LymphomaDiffuse Large B Cell Lymphoma (DLBCL)UB-VV400Rapamycin (sirolimus)
brief summary
This study is a Phase 1/2 dose-finding and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV400. The study will enroll patients with relapsed/refractory B-cell malignancies, including large B-cell lymphoma (LBCL).
started
Aug 1, 2026
primary completion
Aug 1, 2031
completion
Aug 1, 2031
last updated
Jul 30, 2026
official title
A Phase 1/2, Open-label, Multicenter Study of UB-VV400 With Rapamycin in Relapsed or Refractory B-cell Malignancies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol